伏诺拉生四联疗法治疗顽固性幽门螺杆菌感染的效果

摘要
图/表
参考文献(33)
相关文章 (15)

全文: PDF (890 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨伏诺拉生四联疗法治疗顽固性幽门螺杆菌（Hp）感染的效果。方法选取2021 年1 月至12 月南通市海门区人民医院消化科经标准四联疗法根治失败的92 例顽固性Hp 感染患者作为研究对象，采用分段随机法分成观察组（47 例）和对照组（45 例）。观察组采用伏诺拉生+阿莫西林+左氧氟沙星+枸橼酸铋钾治疗；对照组采用艾司奥美拉唑+阿莫西林+左氧氟沙星+枸橼酸铋钾治疗，两组治疗时间均为14 d。停药4 周后复测呼气试验，比较两组Hp 根除率、消化道症状改善情况及不良反应发生情况。结果共85 例（观察组44 例，对照组41例）完成试验。意向性（ITT）分析：观察组Hp 根除率为87.2%，对照组Hp 根除为率57.8%，符合方案集（PP）分析：观察组Hp 根除率为93.2%，对照组Hp 根除为率63.4%。观察组的Hp 根除率高于对照组，差异有统计学意义（P＜0.05）。两组患者Hp 除菌成功后消化道症状评分低于本组治疗前，差异有统计学意义（P＜0.05）。两组的药物不良反应总发生率比较，差异无统计学意义（P＞0.05）。结论伏诺拉生四联疗法对顽固性Hp 感染患者具有较好的根除效果，有效改善消化道症状，无严重不良反应。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：伏诺拉生, 四联疗法, 幽门螺杆菌, 根除率

Abstract：

Objective To explore the efficacy of Vonoprazan based quadruple therapy in refractory Helicobacter pylori infection.Methods A total of 92 refractory Helicobacter pylori(Hp)positive patients who failed to cure with standard quadruple therapy in the Department of Gastroenterology,Nantong Haimen People's Hospital from January to December 2021 were selected as the study objects and they were divided into observation group (47 cases) and control group (45 cases) using stratified randomization.Observation group were treated with Vonoprazan,Amoxicillin,Levofloxacin,Bismuth Potassium Citrate,and control group were treated with Esomeprazole,Amoxicillin,Levofloxacin,Bismuth Potassium Citrate.The treatment course was 14 days in two groups.The 13C-urea breath was retested,and the eradication rate of Helicobacter pylori,improvement of digestive symptoms and incidence of adverse reactions were compared of the two groups after 4 weeks of withdrawal.Results A total of 85 patients (44 cases were in observation group and 41 cases were in control group)completed the experiment.According to the intention-to-treat (ITT),the Hp eradication rates were 87.2%in observation group and 57.8%in control group.According to the per-protocol (PP),the Hp eradication rates were 93.2%in observation group and 63.4%in control group.The Hp eradication rate in the observation group was higher than that in the control group,and the difference was statistically significant (P＜0.05).The gastrointestinal symptom scores of the two groups after successful Hp sterilization were lower than those before treatment in the same group,and the differences were statistically significant(P＜0.05).There was no statistically significant difference in the incidence of adverse drug reactions between the two groups(P＞0.05).Conclusion Vonoprazan based quadruple therapy has better curative effect on eradication of refractory Helicobacter pylori infection,obviously relieve the symptom of digestive tract and has no severe adverse reactions.

Key words： Vonoprazan Quadruple therapy Helicobacter pylori Eradication rate

作者简介: 袁健（1983-），男，江苏南通人，硕士，副主任医师；研究方向：消化道早癌早诊早治。

引用本文:

袁健；黄燕华；陈峰松. 伏诺拉生四联疗法治疗顽固性幽门螺杆菌感染的效果[J]. 中国当代医药, 2024, 31(18): 51-54转63.
YUAN Jian HUANG Yanhua CHEN Fengsong▲. Efficacy of Vonoprazan based quadruple therapy in refractory Helicobacter pylori infection. 中国当代医药, 2024, 31(18): 51-54转63.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2024/V31/I18/51

[1]	Hu Y，Zhu Y，Lu NH.Novel and effective therapcutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance[J].Front Cell Infect Microbiol，2017，7（1）：168-172.
[2]	潘锋.幽门螺杆菌感染与胃肠内外多种疾病相关[J].中国当代医药，2024，31（1）：1-3.
[3]	孙俪铭，岑朝，罗春桃,等.幽门螺杆菌感染对胃黏膜上皮细胞病变的研究进展[J].中国医药科学，2024，14（4）：43-46.
[4]	Hooi JKY，Lai WY，Ng WK，et al.Global prevalence of Helicobacter pylori infection：Systematic review and Meta-analysis[J].Gastroenterology，2017，153（2）：420-429.
[5]	韩一凡，于新娟，王莉莉，等.中国幽门螺杆菌耐药情况研究[J].胃肠病学和肝病学杂志，2017，26（6）：664-669.
[6]	胡伏莲.重视幽门螺杆菌感染治疗中抗生素的合理应用[J].中华医学杂志，2020，100（30）：2321-2323.
[7]	Thung I，Aramin H，Vavinskaya V，et al.Review article：The global emergence of Helicobacter pylori antibiotic resistance[J].Aliment Pharmacol Ther，2016，43（4）：514-533.
[8]	刘文忠，谢勇，陆红，等.第五次全国幽门螺杆菌感染处理共识报告[J].中华内科杂志，2017，56（7）：532-545.
[9]	Liu C，Wang Y，Shi J，et al.The Status and progress of firstline treatment against Helicobacter pylori infection：A review[J].Therap Adv Gastroenterol，2021，14（1）：175-177.
[10]	Tanabe H，Ando K，Sato K，et al.Efficacy of vonoprazanbased triple therapy for Helicobacter Pylori eradication：a multicenter study and a review of the literature[J].Dig Dis Sci，2017，62（11）：3069-3076.
[11]	Ashida K，Honda Y，Sato K，et al.The safety and effectiveness of vonoprazan-based Helicobacter pylori eradication therapy：a prospective post-marketing survcillance[J].Expert Opin Drug Saf，2019，18（12）：1255-1261.
[12]	Saito Y，konno K，Sato M，et al.Vonoprazan-based third-line therapy has a higher eradication rate against sitafloxacin-resistant[J].Cancers，2019，11（1）：116-120.
[13]	Kusunoki M，Yuki M，Ishitobi H，et al.Effect of age on effectiveness of vonoprazan in triple therapy for Helicobacter pylori eradication[J].Intern Med，2019，58（11）：1549-1555.
[14]	Matsumoto H，Shiotani A，Katsumata R，et al.Helicobacter pylori eradication with proton pump inhibitors or potassium-competitive acid blockers：the effect of elari-thromycin resistance[J].Dig Dis Sci，2016，61（11）：3215-3220.
[15]	Horie R，Handa O，Ando T，et al.Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan[J].Helicobacter，2020，25（4）：2695-2698.
[16]	Intention to treat and per protocol analysis in clinical trials[J].Nephrology Carlton，2020，25（7）：513-517.
[17]	Blatchford O，Murray W R，Blatchford M.A risk Score to predict need for treatment for uppergastrointestinal haemorrhage[J].Lancet，2000，356（9238）：1318-1321.
[18]	Van der，Hulst Rw，Tytgat GN.Helicobacter pylori and peptic ulcer disease[J].Scand Gastroenterol Suppl，1996，220：10-18.
[19]	Gisbert JP，Calvet X，Cosme A，et al.Long term follow up of 1000 patients cured of Helicobacter pylori infection following an episode of peptic ulcer bleeding[J].Am Gastroenterol，2012，107（8）：1197-1204.
[20]	Sugano K，Tack J，Kuipers EJ，et al.Kyoto global consensus report on Helicobacter pylori gastritis[J].Gut，2015，64（9）：1353-1367.
[21]	Ford AC，Yuan Y，Forman D，et al.Helicobacter pylori eradication for the prevention of gastric neoplasia[J].Cochrane Database Syst Rev，2020，7（2）：80-83.
[22]	Huh KY，Chung H，Kim YK，et al.Evaluation of safety and pharmacokinetics of bismuth containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication[J].Br J Clin Pharmacol，2021，10（1）：149-153.
[23]	陈团生，陈孝敏.伏诺拉生对幽门螺杆菌阳性消化性溃疡患者的疗效、安全性、复发率及生活质量的影响[J].中外医学研究，2021，19（23）：163-165.
[24]	Abe K，Irie K，Nakanishi H，et al.Crystal structures of the gastric proton pump[J].Nature，2018，556（7700）：214-218.
[25]	Miftahussurur M，Pratama PB，Yamaoka Y.The potential benefits of vonoprazan as Helicobacter pylori infection therapy[J].Pharmaceuticals Basel，2020，13（10）：276.
[26]	Abadi ATB，Ierardi E.Vonoprazan and Helicobacter pylori treatement：a lesson from Japan or a limited geographic phenomenon?[J].Front Pharmacol，2019，10（3）：316.
[27]	Sakurai Y，Mori Y，Okamoto H，et al.Acid-inhibitory effects of vonoprazan 20mg compared with esomeprazole 20mg or rabeprazole 10mg in healthy adult male subjects：a randomised open-label cross-over study[J].Aliment Pharmacol Ther，2015，42（6）：719-730.
[28]	Sakurai Y，Nishimura A，Kennedy C，et al.Safety tolerability pharmacokinetics and Pharmacodynamics of single rising TAK-438 vonoprazan doses in healthy male Japanese/non-Japanese subjects[J].Clin Transl Gastroenterol，2015，6（6）：94-98.
[29]	Inatomi N，Matsukawa J，Sakurai Y，et al.Potassium competitive acid blockers：Advanced therapeutic option for acid-related diseases[J].Pharmacol Ther，2016，168：12-22.
[30]	Kagami T，Sahara S，Ichikawa H，et al.Potent acid inhibition by vonoprazan in comparison with esomeprazole，with reference to CYP2C19 genotype[J].Aliment Pharmacol Ther，2016，43（10）：1048-1059.
[31]	Dong SQ，Singh TP，Wei X，et al.Review：A Japanese population-based Meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy：Is superiority illusion?[J].Helicobacter，2017，22（6）：24-38.
[32]	Scott D，Weeks D，Melchers K，et al.The life and death of Helicobacter pylori[J].Gut，1998，43（1）：56-60.
[33]	Kamada T，Satoh K，Itoh T，et al.Evidence-based clinical practice guidelines for peptic ulcer disease 2020[J].Gastroenterol，2021，56（4）：303-322.